文献速递血栓与止血

苯二氮䓬受体激动剂使用与静脉血栓栓塞风险的真实世界证据

Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2020-08-31

基于台湾索赔数据库的巢式病例对照研究,纳入2002年1月1日至2012年12月31日新开具苯二氮䓬受体激动剂(BZRA)者,识别2800例静脉血栓栓塞(VTE)病例并匹配2800例对照。当前BZRA处方(≤90天)与VTE发生相关(aOR 1.83;95%CI 1.62-2.06),苯二氮䓬类催眠药风险点估计高于非苯二氮䓬类催眠药,氟硝西泮风险更高。

要点

  • 当前BZRA处方(≤90天)与VTE发生相关,aOR 1.83(95%CI 1.62-2.06)。
  • 苯二氮䓬类催眠药aOR 2.00(95%CI 1.45-2.76),非苯二氮䓬类催眠药aOR 1.39(95%CI 1.07-1.81)。
  • 联合使用BZRA、使用BZRA种类数及较高剂量BZRA时VTE风险增加;氟硝西泮aOR 2.99(95%CI 1.43-6.28)。

核心结论

  • 当前BZRA使用可能增加VTE风险;苯二氮䓬类催眠药尤其是氟硝西泮具有更高的VTE风险。

研究设计与样本

  • 巢式病例对照研究,分析台湾索赔数据库2002年1月1日至2012年12月31日至少有一次新BZRA处方记录的患者。
  • 纳入前2年无任何BZRA处方的 new users,识别VTE病例并以疾病风险评分匹配对照。
  • 采用logistic回归模型分析BZRA暴露与VTE风险的关联,并综合评估暴露时长、剂量和BZRA类别。

主要发现

  • 共识别2800例VTE病例和2800例匹配对照。
  • 当前BZRA处方(≤90天)与VTE发生相关(aOR 1.83;95%CI 1.62-2.06)。
  • 苯二氮䓬类催眠药(aOR 2.00;95%CI 1.45-2.76)的VTE风险点估计略高于非苯二氮䓬类催眠药(aOR 1.39;95%CI 1.07-1.81)。
  • 联合使用BZRA、使用BZRA种类数增加及较高剂量BZRA时VTE风险增加。
  • 单药分析中,氟硝西泮使用(aOR 2.99;95%CI 1.43-6.28)的VTE风险高于其他BZRA。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Venous thromboembolism (VTE) is a life-threatening disease, and some studies reported that benzodiazepine receptor agonist (BZRA) use could increase the risk of VTE, but this association lacks population-based evidence. OBJECTIVES: To investigate the association between BZRA use and the risk of VTE. PATIENTS/METHODS: A nested case-control study analyzing Taiwan's claims database was conducted of patients with at least one new BZRA prescription on record from January 1, 2002, to December 31, 2012. We included new users who did not have any BZRA prescriptions in the preceding 2 years and identified cases with VTE and disease risk score matched control subjects. We used a logistic regression model to investigate the association between BZRA exposure and the risk of VTE. The exposure duration, dose, and classes of BZRAs were comprehensively evaluated. RESULTS: We identified 2800 VTE cases and 2800 matched controls. Current BZRA prescription (≤90 days) was associated with VTE occurrence (adjusted odds ratio [aOR]: 1.83; 95% confidence interval [CI], 1.62-2.06). The point estimates of benzodiazepine hypnotics (aOR: 2.00; 95% CI, 1.45-2.76) had a marginally higher risk of VTE than nonbenzodiazepine hypnotics (aOR: 1.39; 95% CI, 1.07-1.81). The VTE risk was increased with combination BZRA use, number of BZRA used, and a higher dose of BZRA. On examination of individual BZRA, the risk of VTE was higher with flunitrazepam use (aOR: 2.99; 95% CI, 1.43-6.28) than other BZRAs. CONCLUSIONS: This study presents that current BZRA use may increase the risk of VTE. Also, benzodiazepine hypnotics, especially flunitrazepam, have a higher risk of VTE.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Chen TY, Winkelman JW, Mao WC, et al. Real-world evidence on the use of benzodiazepine receptor agonists and the risk of venous thromboembolism. J Thromb Haemost. 2020. PMID: 32741123. doi:10.1111/jth.15033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。